Global partnerships Alphamab has established strategic collaborations with CSPC, ArriVent, and Glenmark, and is actively pursuing additional licensing and co-development opportunities regionally and globally, creating multiple entry points for BD outreach and co-therapy opportunities.

Diverse pipeline The company’s pipeline spans ADCs, bispecific antibodies, single-domain antibodies, and next generation dual-payload ADCs, offering multiple product candidates for collaborations, licensing deals, and joint development with pharma partners.

Market-ready asset Envafolimab is the world’s first subcutaneously injected PD-(L)1 inhibitor, providing a strong proof-of-concept and a compelling value proposition for collaboration, licensing, or co-commercialization in immuno-oncology.

Regulatory momentum Active regulatory activity includes NMPA accepting KN026 for second-line or later HER2-positive gastric cancer and INDs for JSKN021, signaling a brisk development pace that can be leveraged for partnership timing and milestone planning.

Strategic expansion Recent leadership additions and ongoing clinical progression, plus a growing US-facing licensing dialogue (Pathos/AstraZeneca linkage) indicate readiness to scale partnerships, joint ventures, and regional commercialization in key markets.